Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

She zeroed in on the explanation: the CML cells from these patients had new mutations in the BCR-ABL kinase domain that prevented imatinib from binding but did not interfere with ATP hydrolysis or ...

Underlying mechanisms that account for this include clonal evolution (as the CML patients progress through the different phases), gene amplification or point mutation in the bcr-abl kinase domain ...

New TKIs are available or in development that are more potent than imatinib for inhibiting Bcr-Abl and have a decreased potential for resistance. With these new agents, patients who develop ...

Here’s what the data revealed. The gene mutations that drive progression in CML are unclear. A new study found that mutations in activated signaling and myeloid transcription factor genes at ...

The previously included indication of adult patients with CML-CP or accelerated-phase CML (CML-AP) harboring the T315I mutation will maintain its reimbursable status on the NRDL. CML is a hematologic ...

Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

As a novel drug, olverembatinib can effectively target BCR-ABL and a spectrum of BCR-ABL mutants, including the T315I mutation. In November 2021, olverembatinib received its first approval in China, ...

In some countries, including the US, Scemblix is also approved in patients with Ph+ CML-CP with the T315I mutation. Scemblix is being studied across multiple treatment lines for Ph+ CML-CP, both as a ...